Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Forty Seven Continues to Outperform

January 17, 2020 0

Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to …

Midday January 16, 2020 Outperforming Prohost Picks

January 16, 2020 0

Outperforming Prohost Picks January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 …

Nektar Is Still a Favorite

January 15, 2020 0

Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk …

An Evaluation of Biotech Firms Part 2

January 14, 2020 0

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) …

The XBiotech Interesting News That Rallied Its Stock

January 14, 2020 0

XBiotech XBiotech (XBIT), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and …

The Beginning of a Nektar Outperformance?

January 11, 2020 0

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement …

Why the Recent Data from the Trial of Moderna’s mRNA Vaccine is Important and Significant

January 10, 2020 2

Moderna's mRNA Vaccine Today could be one of the important early days as Moderna (MRNA) succeeded …

An Evaluation of Biotech Firms Part 1

January 9, 2020 0

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked …

Exelixis’ Good News. Prohost Comprehensive Essay with Informative Real Stories About Biotech Stocks

January 7, 2020 0

Coming Soon at Prohost Biotech We have stories to tell about our picked stocks which we …

Prohost Letter #438 ~ The End of the Year Issue 2019

January 1, 2020 0

Prohost Letter #438 End of the Year Issue 2019 Happy New Year 2020 The NASDAQ reached …

Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

December 30, 2019 0

Cassava Sciences Stock is Rallying Cassava Sciences (SAVA) stock closed on Friday, December 27, 2019 at …

Cassava Sciences: More Positive News in Alzheimer’s Disease

December 30, 2019 0

Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, …

The Week in Review #48 ~ Holiday Edition

December 27, 2019 0

The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You …

More fom the Prohost Portfolio

December 20, 2019 0

More from the Prohost Portfolio with Our Observations Gilead (GILD) has cash and new products reaching …

Regenxbio: Promising Results from RGX-121 Gene Therapy for Mucopolysaccharidosis Type II (MPS II)

December 19, 2019 0

Regenxbio Results from RGX-121 for MPSII Regenxbio (RGNX) announced interim data from Phase I/II trial of …

Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig’s Disease Patients

December 17, 2019 0

Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, …

Amarin: The FDA Approves Vascepa for Lowering Cardiovascular Risk

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Forty Seven Continues to Outperform

Midday January 16, 2020 Outperforming Prohost Picks

Nektar Is Still a Favorite

An Evaluation of Biotech Firms Part 2

The XBiotech Interesting News That Rallied Its Stock

The Beginning of a Nektar Outperformance?

Why the Recent Data from the Trial of Moderna’s mRNA Vaccine is Important and Significant

An Evaluation of Biotech Firms Part 1

Exelixis’ Good News. Prohost Comprehensive Essay with Informative Real Stories About Biotech Stocks

Prohost Letter #438 ~ The End of the Year Issue 2019

Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

Cassava Sciences: More Positive News in Alzheimer’s Disease

The Week in Review #48 ~ Holiday Edition

More fom the Prohost Portfolio

Regenxbio: Promising Results from RGX-121 Gene Therapy for Mucopolysaccharidosis Type II (MPS II)

Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig’s Disease Patients

Amarin: The FDA Approves Vascepa for Lowering Cardiovascular Risk

Exelixis and Genentech (Roche) Combination Beats Untreated BRAF V600-Mutation Positive Advanced Melanoma

Ionis and Alnylam Secured Their Future Prosperity

Nektar at the 61st American Society of Hematology (ASH) Meeting